Visceral leishmaniasis: a lingual presentation in a patient with HIV infection.
The term leishmaniasis covers a series of illnesses caused by the protozoan Leishmania; depending on the patient's immune response, the particular species of the protozoan, and the geography, the condition may manifest itself as cutaneous, mucocutaneous, or visceral disease. Visceral leishmaniasis has often been found as a co-infection associated with the human immunodeficiency virus, particularly in the region of the western Mediterranean. We report the case of an HIV-infected patient with a history of treated laryngeal leishmaniasis who subsequently appeared for treatment with a tumorous lesion on the dorsum of the tongue that was caused by Leishmania infection.
Vázquez-Piñeiro
T
T
Department of Oral Medicine, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Fernández Alvarez
J M
JM
Gonzalo Lafuente
J C
JC
Cano
J
J
Gimeno
M
M
Berenguer
J
J
D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis*; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000965:Antimony / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D016049:Didanosine / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D007827:Laryngitis / Q000188:drug therapy / Q000469:parasitology; D007898:Leishmaniasis, Visceral / Q000175:diagnosis*; D008297:Male; D008536:Meglumine / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000627:therapeutic use; D013030:Spain; D014060:Tongue Diseases / Q000469:parasitology*; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D015215:Zidovudine; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000965:Antimony; D016049:Didanosine